cetuximab + P-HDFL

Cetuximab + P-HDFL is a combination therapy used in cancer treatment, particularly for metastatic colorectal cancer. This regimen combines the targeted monoclonal antibody cetuximab with a chemotherapy protocol known as P-HDFL. ## Components of the Combination **Cetuximab (Erbitux)** is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR). It works by binding specifically to EGFR on both normal and tumor cells, competitively inhibiting the binding of epidermal growth factor and other ligands[5]. This prevents receptor activation and downstream signaling cascades that promote cell proliferation, survival, and tumor growth[5]. **P-HDFL** is a chemotherapy regimen consisting of: - Cisplatin (P) - High-dose 5-Fluorouracil (HDFL) - Leucovorin (folinic acid) This regimen is administered as a 24-hour infusion, with cisplatin and high-dose 5-FU/leucovorin given on specific days of the treatment cycle[7][8]. ## Clinical Applications The combination has shown efficacy in treating: 1. **Metastatic Colorectal Cancer**: Particularly in patients with KRAS wild-type, EGFR-expressing tumors[1][5]. 2. **Metastatic Urothelial Carcinoma**: The P-HDFL component has demonstrated activity with moderate toxicity in this indication[8]. ## Efficacy and Safety P-HDFL as a standalone regimen has shown response rates of approximately 62.5% in metastatic urothelial carcinoma, with median overall survival of 12.3 months and progression-free survival of 10.5 months[8]. The toxicity profile is relatively favorable compared to conventional regimens like M-VAC or CMV. When cetuximab is added to chemotherapy regimens for colorectal cancer, it has been shown to improve progression-free survival, overall survival, and objective response rates compared to chemotherapy alone in patients with KRAS wild-type tumors[1]. ## Administration The P-HDFL regimen typically involves: - Cisplatin 35 mg/m² given as a 24-hour infusion - High-dose 5-FU 2,600 mg/m² as a 24-hour infusion - Leucovorin 300 mg/m² as a 24-hour infusion These are administered on Days 1 and 8 of a 4-week cycle, with only HDFL (5-FU and leucovorin) given again on Day 15[8]. Cetuximab is typically administered at an initial dose of 400 mg/m², followed by weekly doses of 250 mg/m²[4]. ## Mechanism of Action The combination works through complementary mechanisms: 1. **Cetuximab**: Inhibits EGFR signaling, leading to decreased cell proliferation, survival, and angiogenesis[5]. 2. **Cisplatin**: Forms DNA crosslinks, interfering with cell division. 3. **5-FU**: Inhibits thymidylate synthase and incorporates into DNA and RNA, disrupting nucleic acid function[9]. 4. **Leucovorin**: Enhances the cytotoxic effects of 5-FU by stabilizing the binding of 5-FU metabolites to thymidylate synthase. This multimodal approach targets cancer cells through different mechanisms, potentially improving efficacy compared to single-agent treatments.

Other names

Cetuximab + P-HDFLFLAG regimencetuximab + cisplatin + 5-fluorouracil + folinic acid